help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH

This version published online on May 20, 2008
Journal of Clinical Endocrinology & Metabolism, doi:10.1210/jc.2008-0375
A more recent version of this article appeared on August 1, 2008
This Article
Right arrow Author Manuscript (PDF)
Right arrow All Versions of this Article:
93/8/3008    most recent
Author Manuscript (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Frystyk, J.
Right arrow Articles by Fisker, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Frystyk, J.
Right arrow Articles by Fisker, S.
Related Collections
Right arrow Neuroendocrinology and Pituitary

Submitted on February 15, 2008
Accepted on May 9, 2008

Determination of free growth hormone

Jan Frystyk MD, PhD, DMSc*, Caroline Marie Andreasen MD, and Sanne Fisker MD, PhD, DMSc

The Medical Research Laboratories, Clinical Institute, and Medical Department M (Diabetes & Endocrinology), Aarhus University Hospital

* To whom correspondence should be addressed. E-mail: jan{at}frystyk.dk.

Context: Approximately 50% of circulating GH is bound to the high affinity GH-binding protein (GHBP), which is known to affect the pharmacokinetics, bioactivity and quantitative determination of GH. Nevertheless, the presence of GHBP is rarely taken into account in the clinical use of GH measurements.

Objective: To develop an assay for free GH in serum.

Methods: We used ultrafiltration by centrifugation. Due to the small molecular difference between GH and GHBP, the size of GHBP and GHBP-GH complexes was increased by pre-incubation of serum with a monoclonal GHBP antibody (MAb 263).

Results: The ultrafiltration membrane almost completely retained all GHBP (>98.5%) and allowed free passage of unbound GH (>98.4%). Addition of increasing concentrations of GHBP reduced free GH dose-dependently, and measured and calculated levels of free GH changed in parallel. During an insulin-tolerance test (ITT), free and total GH changed in parallel in all individuals (n = 11) and their peak values as well as area under the curves (AUCs) were positively correlated (r = 0.89; P < 0.001 and r = 0.92; P < 0.001, respectively). Of note, the relative levels of free GH (calculated as the AUCs of free to total GH) was inversely correlated with GHBP (r = -0.94; P < 0.001).

Conclusion: It is possible to measure free GH in human serum. Free GH correlated positively with total GH and inversely with GHBP. Measurement of free GH may be a helpful future tool in the management of GH disorders and in studies of GH – GHBP inter-relationships.


Key words: Free GH • ultrafiltration • ITT • GHBP







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2008 by The Endocrine Society